The U.S. Food and Drug Administration approved Rituxan, in combination with certain steroids, to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA).
Rituxan is already approved to treat rheumatoid arthritis, non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
It is an antibody that works by binding itself to a specific protein found on the surface of malignant and normal B-cell lymphocytes, enlisting the body's own immune system to kill marked cells.
source:medscape
No comments:
Post a Comment